within Pharmacolibrary.Drugs.ATC.S;

model S02DA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S02DA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Phenazone (antipyrine) is a non-narcotic analgesic and antipyretic agent historically used for the relief of pain and fever. It is rarely used today due to the development of newer, safer alternatives and is not widely approved for use in modern medicine. In otology, phenazone is sometimes administered as otic drops in combination with other agents for the relief of ear pain.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (mixed gender, ~20–50 years old).</p><h4>References</h4><ol><li><p>Shimizu, H, et al., &amp; Ito, K (2023). Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. <i>Clinical therapeutics</i> 45(12) 1251–1258. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2023.09.025&quot;>10.1016/j.clinthera.2023.09.025</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37953075/&quot;>https://pubmed.ncbi.nlm.nih.gov/37953075</a></p></li><li><p>DeVane, CL, &amp; Nemeroff, CB (2001). Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. <i>Clinical pharmacokinetics</i> 40(7) 509–522. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200140070-00003&quot;>10.2165/00003088-200140070-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11510628/&quot;>https://pubmed.ncbi.nlm.nih.gov/11510628</a></p></li><li><p>Verbeeck, RK (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. <i>European journal of clinical pharmacology</i> 64(12) 1147–1161. DOI:<a href=&quot;https://doi.org/10.1007/s00228-008-0553-z&quot;>10.1007/s00228-008-0553-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18762933/&quot;>https://pubmed.ncbi.nlm.nih.gov/18762933</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S02DA03;
